Profile data is unavailable for this security.
About the company
BICO Group AB, previously Cellink AB is a Sweden-based company, which is primarily involved in the healthcare industry. The Company focuses on the application areas of bioprinting, multiomics, cell line development, and diagnostics. The Company develops and markets technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. The Company’s operations divided in two segments: The Industrial Solutions segment that offers products within precision dispensing and biosensor technology for industrial customers, which make a high-capacity contribution to customers production; and The Laboratory Solutions segment that offers 3Dprinters, single- cell and liquid- dispensing instruments as well as services and consumables related to these products.
- Revenue in SEK (TTM)2.26bn
- Net income in SEK-1.61bn
- Incorporated2016
- Employees837.00
- LocationBICO Group ABLangfilsgatan 9GOETEBORG 412 77SwedenSWE
- Phone+46 3 112874646
- Websitehttps://bico.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ADDvise Group AB (publ) | 1.48bn | 110.80m | 1.58bn | 620.00 | 23.87 | 3.34 | 7.05 | 1.07 | 0.5864 | 0.5864 | 7.84 | 4.20 | 0.5506 | 6.73 | 5.52 | 2,365,224.00 | 4.14 | 3.72 | 5.17 | 4.77 | 47.63 | 48.95 | 7.51 | 5.89 | 1.09 | 2.99 | 0.6608 | 0.9405 | 44.30 | 38.62 | 27.62 | -- | 30.35 | -- |
| Stille AB | 362.16m | 35.58m | 1.73bn | 142.00 | 32.16 | 2.69 | 32.52 | 4.79 | 6.00 | 6.00 | 60.20 | 71.84 | 0.5364 | 1.77 | 7.18 | 3,416,557.00 | 5.27 | 7.03 | 6.35 | 8.19 | 46.76 | 43.93 | 9.82 | 9.85 | 0.9879 | 7.17 | 0.00 | 21.98 | 19.70 | 16.78 | -2.48 | 5.34 | 23.62 | -- |
| Bactiguard Holding AB | 220.81m | -126.19m | 2.17bn | 191.00 | -- | 7.12 | -- | 9.81 | -3.60 | -3.60 | 6.30 | 9.80 | 0.3035 | 4.28 | 6.00 | 1,017,544.00 | -17.35 | -7.56 | -19.82 | -8.81 | 29.87 | 47.91 | -57.15 | -26.28 | 1.64 | -11.90 | 0.4129 | -- | -11.96 | 6.46 | -161.71 | -- | 8.43 | -- |
| Sedana Medical AB (publ) | 164.91m | -22.83m | 2.23bn | 83.00 | -- | 2.26 | 32,795.80 | 13.52 | -0.2299 | -0.2299 | 1.66 | 9.95 | 0.1564 | 1.24 | 8.10 | 2,087,443.00 | -2.17 | -5.77 | -2.28 | -6.08 | 70.50 | 64.06 | -13.85 | -36.13 | 7.38 | -- | 0.0043 | -- | 25.23 | 21.59 | 18.90 | -- | 42.12 | -- |
| Detection Technology Oyj | -1.15tn | -1.15tn | 3.00bn | 478.00 | -- | 3.59 | -- | -- | -- | -- | -- | 4.97 | -- | -- | -- | -- | -- | 9.34 | -- | 11.96 | -- | 47.44 | -- | 8.22 | 3.13 | -- | 0.081 | 53.45 | 5.29 | 2.02 | 7.55 | -18.03 | -14.88 | -9.55 |
| BICO Group AB | 2.26bn | -1.61bn | 3.15bn | 837.00 | -- | 1.06 | -- | 1.39 | -22.34 | -26.39 | 31.73 | 42.97 | 0.3398 | 2.33 | 4.14 | 2,555,996.00 | -24.19 | -- | -27.59 | -- | 50.48 | -- | -71.20 | -- | 1.95 | -13.81 | 0.3933 | -- | 6.09 | -- | -1,889.33 | -- | -- | -- |
| Medistim ASA | 534.20m | 103.18m | 3.52bn | 152.00 | 34.09 | 8.14 | 27.63 | 6.60 | 5.60 | 5.60 | 29.01 | 23.48 | 1.03 | 0.7765 | 6.15 | 3,492,704.00 | 19.95 | 22.93 | 24.07 | 28.52 | 79.02 | 78.25 | 19.31 | 20.64 | 2.99 | -- | 0.0206 | 75.25 | 7.00 | 10.06 | -8.91 | 12.72 | 0.033 | 14.87 |
| Holder | Shares | % Held |
|---|---|---|
| Handelsbanken Fonder ABas of 30 Apr 2024 | 6.99m | 10.12% |
| Fj�rde AP-fondenas of 25 Mar 2024 | 4.44m | 6.42% |
| Tredje AP-fondenas of 31 Jan 2024 | 2.38m | 3.44% |
| Deka Investment GmbHas of 31 Jan 2024 | 1.15m | 1.67% |
| ARK Investment Management LLCas of 10 May 2024 | 1.10m | 1.60% |
| SEB Investment Management ABas of 30 Apr 2024 | 440.98k | 0.64% |
| Storebrand Asset Management ASas of 31 Jan 2024 | 337.08k | 0.49% |
| Mandarine Gestion SAas of 29 Feb 2024 | 170.00k | 0.25% |
| Carnegie Investment Bank AB (Investment Management Denmark)as of 31 Dec 2021 | 162.88k | 0.24% |
| E. �hman J :or Fonder ABas of 31 Mar 2024 | 134.22k | 0.19% |
